Stockscreener 앱 받기
5.71
2.88%
0.16
시장 영업 전:
5.44
-0.27
-4.73%
Opus Genetics Inc 주식(IRD)의 최신 뉴스
Opus Genetics (IRD) price target increased by 23.44% to 9.73 - MSN
Opus Genetics secures up to $155M financing from Oberland Capital - MSN
Craig-Hallum Maintains Opus Genetics(IRD.US) With Buy Rating - Moomoo
Opus Genetics Receives $10.11 Consensus Target Price - National Today
Ideas Watch: What is the earnings history of Opus Genetics IncPortfolio Return Report & Reliable Entry Point Alerts - baoquankhu1.vn
Night Vision Disturbances Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Opus Genetics, Viatris, Nevakar, Vyluma, Pfizer, Allergan, AbbVie - Barchart.com
Night Vision Disturbances Pipeline 2026: MOA, ROA, - openPR.com
Opus Genetics to Present Key Ophthalmology Research at ASCRS Annual Meeting 2026 - Quiver Quantitative
Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting - Bitget
Profit Review: Is Opus Genetics Inc in a consolidation phase2026 Technicals & Community Verified Trade Signals - baoquankhu1.vn
Opus Genetics Receives 'Moderate Buy' Rating from Analysts - National Today
Opus Genetics Enters Strategic Financing Agreement With Oberland Capital - VisionMonday.com
Forecast Cut: Will Opus Genetics Inc be affected by tariffsWeekly Investment Summary & Growth Focused Entry Point Reports - baoquankhu1.vn
Opus Genetics, Inc. (R3X1.F) stock price, news, quote and history - Yahoo Finance UK
Opus Genetics enters change in control bonus agreements with key executives - Investing.com India
Opus Genetics enters change in control bonus agreements with key executives By Investing.com - Investing.com Australia
BTIG Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Opus Genetics Adopts Change-in-Control Executive Bonus Agreements - TipRanks
Opus Genetics Secures Up to $155 Million in Non-Dilutive Funding from Oberland Capital to Advance Gene Therapy Pipeline for Inherited Retinal Diseases - Minichart
Opus Genetics (NASDAQ: IRD) adds change-in-control tax reimbursements - Stock Titan
Opus Genetics Secures Major Non-Dilutive Funding Facility - TipRanks
Opus Genetics Secures Up to $155 Million Notes and Raises $5 Million in Equity Financing - TradingView — Track All Markets
Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital - Bitget
Pullback Watch: How does Opus Genetics Inc correlate with Nasdaq2026 Trends & AI Driven Stock Reports - baoquankhu1.vn
Chardan Capital Initiates Coverage of Opus Genetics (IRD) with Buy Recommendation - MSN
Opus Genetics (IRD) lands $155M Oberland deal to fund gene therapy pipeline - Stock Titan
Opus Genetics, Inc. (IRD) stock price, news, quote and history - Yahoo Finance UK
Opus Genetics secures up to $155M financing from Oberland Capital By Investing.com - Investing.com South Africa
Oberland Capital has officially committed to a $5 million equity investment in Opus Genetics Inc at a price of $4.48 per share. - bitget.com
Opus Genetics Secures Up to $155 Million Financing From Oberland Capital - marketscreener.com
Opus Genetics Inc announced strategic financing agreement with Oberland Capital Management LLC - marketscreener.com
Opus Genetics Inc Announced Strategic Financing Agreement With Oberland Capital Management Llc - TradingView — Track All Markets
Opus Genetics Secures $155 Million Strategic Financing Agreement with Oberland Capital to Advance Gene Therapy Programs - Quiver Quantitative
Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal ... - Bluefield Daily Telegraph
IRD Technical Analysis & Stock Price Forecast - intellectia.ai
Opus Genetics Shows Proper Planning Is Key To Adaptive Trial Design - Clinical Leader
Aug Volume: Can Opus Genetics Inc navigate macro headwinds2026 Spike Watch & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Bull Run: Can Opus Genetics Inc reach all time highs this year2026 Analyst Calls & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Opus Genetics (IRD) Receives Overweight Rating from Cantor Fitzg - GuruFocus
Cantor Fitzgerald Initiates Coverage on Opus Genetics - National Today
Opus Genetics (NASDAQ:IRD) Now Covered by Analysts at Cantor Fitzgerald - MarketBeat
This Live Nation Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Cantor Fitzgerald Initiates Opus Genetics(IRD.US) With Buy Rating, Announces Target Price $15 - Moomoo
Short Interest in Opus Genetics, Inc. (NASDAQ:IRD) Grows By 81.3% - MarketBeat
Risk Analysis: Is Opus Genetics Inc stock a good pick for beginners2026 Macro Impact & Verified Entry Point Detection - baoquankhu1.vn
Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 - Sahm
Loss Report: Will Opus Genetics Inc benefit from current market trends2026 Bull vs Bear & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
2.69%
0.25%
자본화:
|
볼륨(24시간):